A Guideline Review on Treatment-Resistant Schizophrenia: A Focus on Clozapine and other Pharmacotherapeutic Strategies

  


    
CPG

    
Definition of TRS (when to start clozapine)

    
Management Algorithm

  

  


    
APA [14]

    
Persistence of Sx despite adequate Rx Tx: Total    duration of Sx of at least 12 weeks, of at least moderate severity, and    associated with at least moderate functional impairment as determined by    validated rating scales.


      or


      If a prospective medication trial of 2 APs at    least six weeks at adequate dose has not led to Sx reduction of more than    20%, and if the likelihood of substantial Sx improvement (e.g., >50%) is    small.

    
Clozapine with careful monitoring to minimize the    risk of harm*(1B)


      ↓ 


      Augmentation of clozapine with another AP/AD/MS, or


      Augment clozapine/other AP with ECT

  

  


    
BAP [15]

    
Failure to respond to 2 trials of AP medication,    of adequate dose and duration.

    
Clozapine is first-line Tx*(A)


      ↓ 


      Augmentation strategies with clozapine*(B), or


      Combined non-clozapine AP medications*(B), or


      Augmentation strategies with other classes of    medications*(B), or


      High-dose AP medication*(B)

  

  


    
CPA16

    
Two clearly identified adequate but failed AP    trials


      or


      Persistence of 2 or more positive Sx (less than 20%    reduction) of at least a moderate level of severity, or a single positive Sx    with severe or greater severity, following 2 or more adequate trials with    different AP medications.

    
Clozapine should be offered as first-line    treatment*(B)


      No consistent evidence to support the use of high    doses, switching, or combining AP medications

  

  


    
RANZCP17

    
Continued positive Sx after trials of at least 2    different APs at moderate doses (usually at least 300 mg of chlorpromazine    equivalents per day) for a reasonable period (usually at least 6 weeks).


      Tx-resistant disease should be recognized within    6-12 months of starting potentially effective AP Tx and confirmed as soon as    possible.

    
Clozapine is first-line Tx*(I)


      ↓ 


      If no response and/or side effects are severe, a    switch is suggested


      ↓ 


      When clozapine monotherapy is ineffective,    augmentation with other medicines or ECT*(III-1)

  

  


    
NICE18

    
Lack of satisfactory clinical improvement despite    the use of adequate doses of at least 2 different AP medications, including    an atypical AP, prescribed for adequate duration (at least 4 weeks each)


      or


      ‘Incomplete recovery’ defined as the presence of    lasting disability in functional and psychosocial aspects despite    psychological/psychosocial and Rx interventions, while also recognizing the    potential for improvement.

    
Clozapine is first-line Tx


      ↓ 


      If response to clozapine monotherapy is poor,    augmentation strategies are considered, or


      High-dose AP medication

  

  


    
SIGN19

    
Failure to respond to an adequate trial of 2    different AP medications, including a SGA.

    
Clozapine should be offered as first-line Tx*(B)


      ↓ 


      Clozapine augmentation with another AP*(C)


      ↓ 


      Clozapine augmentation with other medications*(B)a, or


      Switching to another AP, or


      High-dose AP medication*(D), or


      ECT*(C)

  

  


    
WFBSP20

    
A situation in which a significant improvement of    psychopathology and/or other target symptoms has not been demonstrated    despite Tx with 2 different AP medications from at least 2 different chemical    classes (at least one should be an atypical AP), at the recommended AP    dosages for a Tx period of at least 2–8 weeks per drug trial.

    
Clozapine is first-line Tx*(B)


      Switch to another SGA*(B), or


      Combination of clozapine with another SGA    (possibly risperidone)*(C), or


      AP combination therapy*(C), or


      Combination with other neuroactive drugsb:    AD, anxiolytics, etc.,


      or


      ECT*(D)

  

  


    
Legend: CPGs:    Clinical Practice Guidelines; APA: American Psychiatric Association; BAP: British    Association for Psychopharmacology; NICE: National Institute for Health and    Care Excellence; RANZCP: Royal Australian and New Zealand College of    Psychiatrists; CPA: Canadian Psychiatric Association; SIGN: Scottish    Intercollegiate Guidelines Network; WFSBP: World Federation of Societies of    Biological Psychiatry; Sx: Symptoms; Rx: Pharmacological; Tx: Treatment; AP: Antipsychotic;    AD: Antidepressant; MS: Mood Stabilizer; ECT: Electroconvulsant Therapy; SGA:    Second Generation Antipsychotics.


      *Level    of evidence or grade of recommendation, as per the specific clinical practice    guideline (described in Table 1); aThis level of evidence is only    reported in combination with lamotrigine; bDepending on the drug,    the level of evidence is varied from B to F.

  

Table 4: Definition and recommendations for the management of TRS in the schizophrenia CPGs.

Discussion

Relevant findings of this review of seven CPGs reveal that clozapine has strong evidence for important efficacy outcomes in schizophrenia, such as:

Reduction of mortality: No large, long-term, Randomized Controlled Trials (RCTs) have studied the effects of clozapine or of other antipsychotic medications on mortality. However, the results of two large pharmaco-epidemiological cohort studies have consistently shown that treatment with clozapine is associated with a reduction in all-cause mortality in patients with schizophrenia [23,24]. In one of these studies, the mortality rate also increased one year after clozapine discontinuation [24]. These findings are consistent with results of a recent meta-analysis where the mortality rate was reported to be significantly lower in patients who are continuously treated with clozapine as compared to those treated with other antipsychotics [25].

Decreased hospitalization: The hospitalization rate among patients with schizophrenia is high, regardless of the stage of the disease [26-28]. This may be due to relapse, non- compliance, or no response to treatment. Even though clozapine is usually started while patients are in hospital, studies have consistently shown that treatment with clozapine is associated with a reduction in hospitalization and re-hospitalization rates by 20-30%, especially when it is used in patients with suicidal or aggressive behavior [29-34]. Combination of clozapine with other antipsychotics, such as aripiprazole, has shown even better reduction in hospitalization rates when compared to clozapine alone [32,34].

Decreased relapse rate: There are a few head-to-head studies comparing different antipsychotic medications in relapse prevention. All Second-Generation Antipsychotics (SGAs) have shown superiority over First-Generation Antipsychotics (FGAs), and thus are recommended as first-line in all the schizophrenia guidelines reviewed [6,35,36]. However, CPGs do not recommend any particular SGA for relapse prevention. Clozapine and Long Acting Injectable Antipsychotics (LAIAPs) have been reported as having the highest relapse prevention rates [22]. Because LAIAPs are known to improve adherence in schizophrenia [37], some guidelines are recommending their use in combination with clozapine for relapse prevention [15,17].

Increased adherence: Non-adherence to treatment has been associated with negative patient outcomes, such as becoming aggressive, increased risk to self-harm and increased likelihood of substance misuse [38-40]. Thus, it has been suggested that the efficacy of clozapine in the management of patients with suicidal or aggressive behavior may be due to improved adherence while on clozapine treatment [33]. Both, APA and BAP guidelines provide several strategies for improving adherence in schizophrenia, such as the use of LAIAPs, regular contact with patients, or measuring the medication’s plasma concentration [14,15].

Cost-effectiveness: Results of the CUtLASS band 2 study, which compared clozapine with other SGA medications, clozapine showed to be more efficacious but resulted in higher treatment costs [41]. However, the NICE guideline attributes the higher costs possibly because, at the time when the study was conducted, patients needed to be hospitalized to start clozapine therapy [18]. As clozapine treatment can nowadays be initiated in an outpatient setting in most countries, there is a need for its cost-effectiveness to be re-examined, particularly in TRS. Overall, costs of clozapine treatment differ by country and geographic region, as well as in the payment models throughout different health systems [14,15].

Clozapine indications in people with schizophrenia

Management of TRS: All the schizophrenia CPGs reviewed provided strong supporting evidence on clozapine’s efficacy in the management of TRS and was recommended as the agent of first choice for this indication. The main difference among the CPGs was in relation to the definition of TRS, and on recommendations about when to start clozapine in the course of the disease. It has been suggested that variations in these definitions are the result of an inconsistent criteria used to include patients with TRS in clinical trials [4]. In addition, key aspects of determining treatment resistance, such as adherence to prior antipsychotic use, is not consistently assessed [10]. Another important difference in the recommendations provided in the schizophrenia CPGs is in regards to the treatment of choice for patients experiencing Clozapine Resistance (CR). The WFBSP and the RANZCP guidelines suggest switching to another SGA as monotherapy before considering augmentation strategies, while the other guidelines recommend augmentation with antipsychotic medications as the first step. These are mostly low-grade recommendations, as evidence from RCTs for the management of CR among TRS patients is limited and mostly supported by unpowered studies [32,42]. Some CPGs recommend to consider combination with medications with a complementary receptor profile to clozapine, but with a different safety profile [14,15].

The last treatment option for patients with TRS recommended in the CPGs reviewed is the use of Electroconvulsant Therapy (ECT) alone or as adjuvant. Although there are limited number of studies on the use of ECT in TRS, the results are generally positive in terms of safety and efficacy [43,44]. ECT has shown to reduce the rate of relapse in TRS when added to clozapine. However, this is only reported for patients who showed benefit from ECT before meeting the criteria for TRS [45]. A recent international initiative of experts in the field of schizophrenia developed consensus recommendations for the management of CR TRS patients [34]. Raising clozapine plasma levels to ≥350 ng/ml for CR patients with positive, negative, and mixed symptoms was recommended. For CR patients with mostly positive symptoms, combination with a SGA (such as amisulpride or oral aripiprazole), and augmentation with ECT or with a moodstabilizer or with another antipsychotic medication (particularly for TRS patients with CR aggressive symptoms) were recommended. For CR patients with predominant negative symptoms, augmentation with an antidepressant or with a mood-stabilizer (particularly for TRS patients with CR suicidality) and ECT were recommended [34].

Other indications: Other schizophrenia-related indications for clozapine that were generally supported with relatively high levels of evidence in the CPGs was the management of aggressive behavior and of suicidal risk. Numerous studies have demonstrated the superiority of clozapine over other antipsychotic medications in reducing the rates of self-harm, suicidal attempts, and suicidal mortality [24,46-48]. The anti-hostility effect of clozapine has also consistently been demonstrated in several studies regardless of any symptom improvement (positive or negative) [30,33,49].

The WFSBP was the only guideline that provided supportive evidence for the use of clozapine in first episode psychosis (FEP) [20]. Recent studies have shown significant higher rates of remission and lower rates of re-hospitalization in treatment naïve patients who treated with clozapine compared to those who were given different antipsychotics [50-53]. Studies have also shown a response rate of 75-80% when clozapine was initiated early in the treatment of schizophrenia [54]. However, most CPGs do not recommend initiating clozapine for FEP primarily due to safety concerns, particularly its hematological risk profile [14,15,17,20]. In addition, concerns about a higher incidence of adverse effects in younger patients (who are likely those experiencing FEP) have been reported [55,56]. Only the WFSBP and SIGN guidelines provide general statements on the efficacy of clozapine in treating primary negative symptoms [19,20]. No studies were found on clozapine’s efficacy on primary negative symptoms compared to placebo. Although studies have shown that clozapine is effective for the treatment of negative symptoms when compared to FGA and some SGAs, in trials that lasted longer than 3 months, the efficacy of FGA on negative symptoms was not significantly different than when using SGAs [30,33,57-63]. In general, based on the recommendation provided in the CPGs reviewed, there is no pharmacological treatment for the management of primary negative symptoms. Further studies are needed to address the specific role of clozapine in this indication.

Clozapine’s safety profile

Our review identified that overall CPGs provided limited information about certain aspects of clozapine’s safety profile and monitoring recommendations. Agranulocytosis is the most serious, but rare, side effect of clozapine, but its incidence has significantly been reduced from 1-2% (when first reported) to 0.9% [64]. This was mostly achieved because of the mandatory hematological monitoring that is required for all patients during the first year of clozapine treatment [65,66]. Although all the CPGs promote adherence to the monitoring requirements in order to ensure positive efficacy and safety outcomes in patients with TRS, there are discrepancies in regards to the required hematological monitoring among all the CPGs. Some guidelines are very prescriptive, for example, the APA requires that clozapine prescribers register under the Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) program, which requires weekly hematological monitoring from initiation to 6 months, followed by every 2 weeks from 6 to 12 months [14], while the NICE guideline only recommends routine monitoring without being too prescriptive [18]. Considering that this particular safety aspect of clozapine is associated to clinicians preferring the use of less effective treatment options [67], it is important that consensus among the different CPGs is established in regards to the optimal (and safest) frequency of hematological monitoring. Another aspect of limited information on all the CPGs is in relation to clozapine’s interactions with smoking. Only APA, NICE, and RANZCP guidelines describe the effect of smoking on clozapine metabolism and how to manage schizophrenia treatment among smokers [14,17,18]. Smoking induces the main enzyme system responsible for the metabolism of clozapine (particularly CYP 1A2), leading to a potential reduction of clozapine plasma levels by up to 50% [68-70]. Therefore, higher doses of clozapine are required to achieve the therapeutic plasma levels in smokers. However, the majority of the schizophrenia CPGs do not sufficiently address this interaction in the smoker population. Recommendations, such as offering patient smoking cessation therapies, dose adjustments and monitoring of clozapine plasma levels, to minimize the potential decreased efficacy of clozapine among smokers, need to be consistently provided in CPGs.

Conclusions and Recommendations

A total of seven schizophrenia CPGs were identified in this systematic review of the literature, and vary in the scope of information presented. Numerous recommendations were consistently provided across all the CPGs reviewed, which would assist in clinical decision making when treating patients experiencing TRS, including:

• Clozapine remains the first treatment option with the strongest supportive evidence.

• Clozapine monotherapy is preferred. There is lack of evidence in support of antipsychotic polypharmacy.

• The evidence for augmentation of medications for clozapine refractory (CR) patients is limited, and mostly supported by unpowered studies.

This study also helped to identify some gaps in our knowledge about TRS treatment. Main differences in the recommendations provided were in relation to the definition of TRS, on the management of TRS patients who do not respond to clozapine treatment, on the breath of information in relation to clozapine’s safety profile, and on the frequency of hematological monitoring, that is required during clozapine treatment.

Future iterations of CPGs should seek consensus on certain aspects of TRS, particularly in regards to a clear definition of TRS and standardized measurements of response to treatment. As the safety profile of clozapine appears to be the main limiting factor for starting clozapine, CPGs should also provide support and advice on strategies to address them, such as implementation of clozapine clinics, multidisciplinary team involvement, and smoking cessation programs.

Declaration

Acknowledgements: We extend our thanks to the students in the Doctor in Pharmacy program at College of Pharmacy, Qatar University, who through their clinical rotations in mental health practice contributed to the literature review.

Author contributions: MZ contributed to the conception, design, and research protocol, in addition to being involved in all aspects of data analysis and manuscript revisions for intellectual content MN contributed to data collection, data analysis, and preparation of the manuscript. YE and OA contributed to the data collection process and critically revising the manuscript.

References

1. Kane JM. Addressing nonresponse in schizophrenia. J Clin Psychiatry. 2012; 73: e07.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45: 789-796.
3. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012; 197: 1-6.
4. Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174: 216-229.
5. Miyamoto S, Jarskog LF, Fleischhacker WW. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. J Psychiatr Res. 2014; 58: 1-6.
6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second- generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158: 518-526.
7. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006; 32: 715-723.
8. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163: 600-610.
9. Fayek M, Flowers C, Signorelli D, Simpson G. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatr Serv. 2003; 54: 1453-1454, 1456.
10. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012; 201: 481-485.
11. Ismail D, Tounsi K, Zolezzi M, Eltorki Y. A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries. Asian J Psychiatr. 2019; 39: 93-97.
12. Kelly D, Kreyenbuhl J, Buchanan R, Malhotra A. Why not clozapine? Clinical Schizophrenia & Related Psychoses. 2007; 1: 92-95.
13. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014; 14: 102.
14. American Psychiatric Association. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Pub. 2020.
15. Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020; 34: 3-78.
16. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017; 62: 604-616.
17. Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016; 50: 410-472.
18. National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition. London: National Institute for Health and Care Excellence (UK). 2014.
19. Scottish Intercollegiate Guidelines Network (SIGN). Management of schizophrenia. A national clinical guideline. SIGN 131.
20. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012; 13: 318-378.
21. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. WFSBP task force on treatment guidelines for schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14: 2-44.
22. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015; 16: 142-170.
23. Cho J, Hayes RD, Jewell A, Kadra G, Shetty H, MacCabe JH, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand. 2019; 139: 237-247.
24. Wimberley T, MacCabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, et al. Mortality and Self-Harm in Association With Clozapine in Treatment- Resistant Schizophrenia. Am J Psychiatry. 2017; 174: 990-998.
25. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1- 12.5 years. Schizophr Bull. 2019; 45: 315-329.
26. Helgason L. Twenty years’ follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr. Scand. 1990; 81: 231-235.
27. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994; 151: 1409-1416.
28. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161: 1-56.
29. Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017; 135: 296-309.
30. Meltzer HY. Suicide in schizophrenia, clozapine, and adoption of evidencebased medicine. J Clin Psychiatry. 2005; 66: 530-533.
31. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients With Schizophrenia. JAMA Psychiatry. 2017; 74: 686-693.
32. Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019; 76: 499-507.
33. Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci. 2014; 26: 283-312.
34. Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, et al. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia - Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull. 2020; 46: 1459-1470.
35. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18: 53-66.
36. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003; 160: 1209-1222.
37. Salgueiro M, Segarra R. Long-acting injectable second-generation antipsychotics in first- episode psychosis: a narrative review. Int Clin Psychopharmacol. 2019; 34: 51-56.
38. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67: 453-460.
39. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003; 12: 423-424.
40. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010; 176: 109-113.
41. Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health. 2008; 11: 549-562.
42. Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74: 675-684.
43. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005; 21: 75-83.
44. Chanpattana W, Sackeim HA. Electroconvulsive therapy in treatmentresistant schizophrenia: prediction of response and the nature of symptomatic improvement. J ECT. 2010; 26: 289-298.
45. Chanpattana W, Chakrabhand ML, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P, et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT. 1999; 15: 178-192.
46. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta- analysis. Schizophr Res. 2005; 73: 139-145.
47. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003; 60: 82-91.
48. Wagstaff A, Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs. 2003; 17: 273-280; discussion 281-283.
49. Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15: 1351-1371.
50. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011; 199: 281-288.
51. Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand. 2018; 138: 281-288.
52. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168: 603-609.
53. Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017; 4: 694-705.
54. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72: 1439-1444.
55. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014; 71: 1350-1363.
56. Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund B, et al. Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapineextended release versus aripiprazole: 12-week results from the tolerance and effect of antipsychotics in children and adolescents with psychosis (TEA) trial. J Am Acad Child Adolesc Psychiatry. 2019; 58: 1062-1078.
57. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009; 2009: CD000059.
58. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta- analysis. Lancet. 2019; 394: 939-951.
59. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol. 1994; 14: 201-204.
60. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010: CD006633.
61. Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs. Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta- analysis of Cohort Studies. JAMA Psychiatry. 2019; 76: 1052-1062.
62. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry. 2016; 73: 199- 210.
63. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine vs. first- and second- generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016; 209: 385-392.
64. Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018; 138: 101-109.
65. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapineinduced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329: 162-167.
66. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapinerelated morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998; 59: 3-7.
67. Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017; 6: CD009005.
68. Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016; 55: 1353-1368.
69. Scherf-Clavel M, Samanski L, Hommers LG, Deckert J, Menke A, Unterecker S. Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Int Clin Psychopharmacol. 2019; 34: 93-100.
70. Taylor DM, Barnes T, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons. 2018.